Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities ... was initiated Friday by the FDA and CDC while the two federal agencies ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events. Two ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

“While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, the FDA and CDC are recommending a pause in the use of the vaccine in this age group ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities ... was initiated Friday by the FDA and CDC while the two federal agencies ...

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued advisories late last week regarding the vaccine Ixchiq, developed by Valneva. Chikungunya is ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...